<DOC>
	<DOC>NCT01746862</DOC>
	<brief_summary>This is an open-label, multi-center, randomized, two-arm parallel, no-treatment group controlled (only for the first 6 months), Phase 3 study in children with ISS. The subjects will be treated with 0.067 milligram/kilogram/day (mg/kg/day) of Saizen®, weight base dose, for 12 months (12 months of treatment in the test group, and 6 months of no treatment and then 6 months of treatment in the control group).</brief_summary>
	<brief_title>A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism</mesh_term>
	<criteria>Age greater than or equal to 5 years Prepubertal; testicular volume less than 4 milliliter (in males) and breast Stage 1 (in females) The official records of height (for example records measured in hospitals or schools) during previous 6 months or more preceding inclusion in the study (selfmeasurement of the height at home will not be considered as a valid record) Height less than or equal to 3rd percentile compared to same sex, same age Peak serum growth hormone (GH) greater than 10 microgram per liter (mcg/L) in GH stimulation test (results of peak serum GH greater than 10 mcg/L in GH stimulation test within 1 year can be used instead) Naive to GH therapy Normal birth weight (that is greater than or equal to 3rd percentile when compared to same sex) Normal thyroid function Normal karyotype in girls Written informed consent from parent/guardian Written informed consent from the subject who speaks, understand, read, and write Korean Bone age less than 10 years in boys and less than 9 years in girls, whose difference between the bone and chronological age is no more than 3 years Puberty development (Tanner stage greater than or equal to 2) Skeletal dysplasia or abnormal body proportions Chronic systemic illness Dysmorphic syndrome Growth Hormone Deficiency Small for Gestational Age (SGA) Current medication for Attention deficit hyperactivity disorder (ADHD) or hyperactivity disorder Current medication with drugs that may influence secretion or action of growth hormone (such as estrogen, androgen, anabolic steroid, corticosteroid, thyroxine, aromatase inhibitors) Diabetes mellitus Kidney transplantation Acute critical illness, including complications following open heart surgery, abdominal surgery or multiple accidental trauma Acute respiratory failure Malignancy or previous therapy for malignancy Known hypersensitivity to somatotropin or any of its excipients including cresol or glycerol Closed epiphyses, progression or recurrence of an underlying intracranial tumor, chronic renal disease Endocrinologic or metabolic disorders such as PraderWilli syndrome; RusselSilver syndrome; Seckel syndrome; Down syndrome; Cushing syndrome; Noonan syndrome; short stature caused by other chromosomal abnormalities The disorders that explain short stature such as psychiatric disorders, nutritional disorders, and chronic debilitating diseases Participation in another clinical trial within the past 3 months Status of legal incapacity or limited legal capacity of the parents or legal guardian</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Saizen®</keyword>
	<keyword>Recombinant human growth hormone (r-hGH)</keyword>
	<keyword>Idiopathic short stature</keyword>
	<keyword>Height velocity</keyword>
	<keyword>Bone age</keyword>
</DOC>